MedTrace Logo

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

NCT02188173 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2016-06-01

No results posted yet for this study

Summary

This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).

Conditions

  • Macular Edema

Interventions

DRUG

dexamethasone 700 ㎍ intravitreal implant

Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02188173 on ClinicalTrials.gov